Henry Meds vs Mochi Health (2026): The Real Cost Difference at Maintenance Dose

Prices as of May 2026. Compounding legal status current as of May 22, 2025 enforcement deadline. See our compounding tracker for weekly updates.

The short answer

Choose Henry Meds if you are starting on semaglutide, want an all-inclusive price with no separate membership fee, and expect to stay at a low-to-mid dose.

Choose Mochi Health if you are targeting tirzepatide, expect to reach maintenance dose, have commercial insurance that might cover a brand-name GLP-1, or want live video consults with an obesity medicine specialist.

The pricing gap narrows and then reverses as dose increases. That reversal is the most important number in this comparison, and most review sites miss it.

At-a-glance comparison

Pricing in depth: the maintenance-dose trap

This is the section most comparison sites skip.

Both providers quote appealing starter prices. Henry Meds’ all-in bundle for semaglutide runs approximately $247/mo for the first month and $297/mo on a recurring basis at standard dose. Mochi’s true monthly total is $178/mo ($99 drug + $79 membership).

Henry Meds starts cheaper. But that advantage erodes with every dose increase.

Henry Meds uses a tiered pricing structure in which each dose step-up costs approximately $100/mo more. A patient who titrates from a starting dose to a mid-maintenance dose over six months can see their monthly bill climb from $297 to $397 or beyond — without changing providers or programs. The $100-per-tier surcharge is disclosed on Henry Meds’ program terms page, but it is easy to miss in an intake flow that quotes only the first month’s rate.

Mochi charges a flat $99/mo for compounded semaglutide regardless of dose. Dose increases do not trigger a price change. For a patient who reaches and holds a mid-to-high maintenance dose, Mochi’s $178/mo total is meaningfully cheaper than Henry’s $397+/mo.

Six-month cost illustration (semaglutide, titrating to maintenance)

Month	Henry Meds	Mochi Health
1–2 (starter dose)	$247–$297	$178
3–4 (mid dose)	$297–$397	$178
5–6 (maintenance)	$397+	$178
6-month total	~$2,130	~$1,068

Figures are illustrative based on publicly stated pricing as of May 2026. Dose progression varies by patient; your prescriber determines your titration schedule.

For tirzepatide, Mochi wins from the first month. Henry Meds lists tirzepatide at $399/mo (first month) and $449/mo recurring. Mochi charges $199/mo flat for compounded tirzepatide plus the $79/mo membership — $278/mo total. That is a $121–$171/mo saving in Mochi’s favour, at every dose level.

Compounding status and legal risk

Both Henry Meds and Mochi Health operate under the §503A(b)(1)(D) exemption — currently the only active legal pathway for compounded semaglutide and tirzepatide in the US. The 503B outsourcing pathway for GLP-1 bulk substances expired on May 22, 2025. For a detailed breakdown of the two pathways and their current status, see our compounding tracker.

Mochi Health’s litigation exposure

Eli Lilly filed suit against Mochi Health Corp., Mochi Medical CA P.C., Mochi Medical P.A., and Aequita Pharmacy LLC in April 2025 (Case No. 3:25-cv-03534-JSC, Northern District of California). The allegations centre on false advertising under the Lanham Act and unfair competition under California law — specifically that Mochi marketed compounded tirzepatide as equivalent to FDA-approved Zepbound after the shortage justification ended.

Mochi moved to dismiss. Judge Jacqueline Scott Corley initially granted the first dismissal but allowed Lilly to amend its complaint. On a renewed motion to dismiss, the court again denied Mochi’s bid in April 2026, finding Lilly’s amended complaint adequately alleged economic harm through lost sales diversion. The Lanham Act and California UCL claims are proceeding to discovery. Lilly’s civil conspiracy claim was dismissed with leave to amend.

The case is active and unresolved. It does not currently prevent Mochi from operating, but it represents a material regulatory overhang.

Henry Meds’ litigation exposure

Henry Meds (Adonis Health Inc) faces separate Eli Lilly litigation. In 2026, a court partially denied Henry Meds’ motion to dismiss: the claim that Henry used the term “personalized” in advertising survived; the “safe and effective” claim was dismissed. No FDA warning letter has been issued to Henry Meds as of May 2026.

Neither provider has received a compounding-specific FDA enforcement action under the current §503A framework, though both operate in an area of active enforcement interest.

Insurance path: Mochi has it; Henry does not

Henry Meds is a cash-pay-only program. No insurance navigation, no prior authorisation support, no HSA/FSA integration mentioned in programme terms.

Mochi Health does not bill insurance for compounded medications. However, if your commercial plan covers brand-name GLP-1s, Mochi’s team handles the prior authorisation process and letters of medical necessity directly with your insurer. They will also bridge you with compounded medication while the PA is under review (per Mochi’s FAQ; insurers have up to 30 days to respond). HSA and FSA funds are accepted for Mochi services.

This matters more than it sounds. Commercial insurance prior authorisation for Wegovy or Zepbound can reduce a patient’s effective monthly cost to a copay, or to zero if their plan has full coverage. Mochi is the only provider in this comparison that creates that path. Henry Meds does not.

Program model: bundled simplicity vs layered membership

Henry Meds bundles everything — provider consultation, medication, shipping, supplies, anti-nausea medications — into one quoted price. There is no separate membership fee. The intake quiz leads to a prescription review within 1–3 days, often asynchronously. Check-ins occur every 60–90 days. There are no scheduled video appointments in the standard programme. For patients who want low friction and an all-in line item on their credit card statement, this model is appealing.

Mochi Health operates a two-line structure: a $79/mo membership that covers all clinical services (live video consultations with board-certified obesity medicine specialists, registered dietitian access, 24/7 messaging support, PA support) plus a separate flat-rate medication charge. The membership model looks more expensive upfront but includes more clinical infrastructure — notably live video with specialists who hold ABOM board certification in obesity medicine, something Henry Meds’ async model does not replicate.

From patient accounts, Mochi’s video-first model creates a different clinical relationship. As one reviewer on r/Semaglutide noted: “Mochi is the only telehealth that had me talk face to face over video call with a real NP.” Whether that depth is worth the incremental cost is a personal calculation, but for patients with complex metabolic histories, comorbidities, or prior medication failures, a live specialist encounter has real value.

Clinical quality signals

Trustpilot scores are similar: Henry Meds at 4.5/5 across 12,000+ reviews, Mochi at 4.4–4.5/5 across 15,000+ reviews. One important note: Trustpilot’s algorithms flagged Henry Meds’ review page with a pattern inconsistency notice, indicating detected behaviour inconsistent with organic review activity. Trustpilot does not confirm reviews are fake when it issues such a notice, but it warrants scepticism about the signal.

BBB is negative for both, and it is worth understanding why. Both Henry Meds and Mochi Health carry an F rating from the Better Business Bureau. Henry Meds has logged approximately 25 formal complaints with 100% non-response — the non-response is what drives the F grade, not a resolution record. Mochi has over 1,200 BBB complaints, predominantly billing and cancellation disputes. Neither pattern indicates a medical harm record; both indicate customer service friction that is real and documented.

The practical signal: Mochi’s larger complaint volume reflects greater scale as much as worse performance. Henry Meds’ 100% non-response to the BBB complaint process is the more structurally concerning data point.

Supply reliability

Mochi Health and the Aequita disruption is the more significant supply history of the two.

In March 2025, the Washington State Pharmacy Quality Assurance Commission issued a Limited Stop Service order against Aequita Pharmacy LLC — one of Mochi’s primary compounding partners. The violations were material: the commission found untrained and unqualified staff performing sterile compounding, inadequate supervision, and failure to adhere to sterile compounding procedures required to ensure product integrity. The same Aequita entity is named as a co-defendant in the Lilly lawsuit.

Mochi transitioned affected patients to other compounding pharmacies and continued operating. Patients reported fulfilment delays during the transition period, but the programme did not shut down. Mochi now uses multiple compounding partners (including Casa Pharmacy, as reported by patients), reducing single-vendor concentration risk.

Henry Meds has not had a disclosed pharmacy partner shutdown, but it does not publicly identify its compounding partners, which limits any independent quality assessment. Independent testing of compounded semaglutide from various unnamed telehealth pharmacies has found impurity issues industry-wide; the absence of disclosed partners makes provider-specific quality verification impossible for Henry Meds patients.

Both providers recommend initiating refills early — fulfilment timelines of 7–14 business days are advertised, but real-world patient accounts frequently describe 2–4 week delays. Medication gaps on GLP-1s are clinically uncomfortable; patients who have been on these medications for months know that abrupt lapses can partially reverse appetite-suppression effects.

Who chooses Henry Meds

Henry Meds is the better fit if:

• You are starting on semaglutide and expect to stay at a low or standard dose
• You want an all-in monthly price with no separate membership fee
• You prefer an async model (no scheduled video calls) and a quick intake process
• You are on a tight budget and the starting price difference matters more than long-term cost modelling
• You want access to oral/sublingual semaglutide or tirzepatide formats (Henry offers more format variety than most competitors)

Be cautious about Henry Meds if:

• You plan to titrate to maintenance dose — the $100/tier surcharge will erode your cost advantage
• You have insurance that might cover Wegovy or Zepbound — Henry offers no path to exploit that benefit
• You want a live clinical relationship with an obesity medicine specialist

Who chooses Mochi Health

Mochi Health is the better fit if:

• You are targeting tirzepatide (Mochi is cheaper at every dose level)
• You expect to reach and stay at maintenance dose (flat rate means no cost surprises)
• You have commercial insurance and want someone to fight for PA on brand-name GLP-1s
• You have a complex metabolic history, prior medication failures, or comorbidities that benefit from specialist oversight
• You want dietitian access built into your programme
• You are comfortable with a two-line pricing model and understand the membership fee is not a hidden add-on

Be cautious about Mochi Health if:

• The Aequita supply disruption history concerns you (though Mochi now uses multiple partners)
• The active Lilly litigation creates a comfort threshold you cannot get past
• Billing/cancellation friction is a dealbreaker — the BBB complaint pattern is real

FAQ

Pricing figures are sourced from provider programme terms pages and independent review aggregators as of May 2026. Compounding legal status reflects the regulatory landscape as of the May 22, 2025 enforcement deadline. Litigation status is current as of April 2026. Neither this publication nor its editors are affiliated with Henry Meds or Mochi Health. All affiliate relationships are disclosed inline per FTC 16 CFR 465; this article contains no affiliate links. For the latest compounding provider status, see our compounding tracker.

Related: Henry Meds full review · Mochi Health full review · Compare all GLP-1 providers